Integrity Capital Management (HK)’s Class Acceleration Corp. Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 CLAS.WS Stock Holding History
Bought
Maintained
Sold
Other funds holding CLAS.WS
MP
AFM
RCM
LP
ICM
FBCM
PC
FTCM
Integrity Capital Management (HK)'s CLAS.WS Position: Q2 2022 in Review
Integrity Capital Management (HK) sold out of Class Acceleration Corp. Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 (CLAS.WS) in Q2 2022, closing a stake of 5,954 shares — an estimated $1K sold.
Integrity Capital Management (HK) first reported a position in CLAS.WS in Q4 2021 and held it in 2 quarters. The position peaked at $26K in Q4 2021. 44 funds tracked by Wall St. Rank hold CLAS.WS as of Q2 2022.
- Integrity Capital Management (HK) reported no remaining Class Acceleration Corp. Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 position as of Q2 2022 after selling out during the quarter.
- Integrity Capital Management (HK) sold 5,954 Class Acceleration Corp. Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 shares in Q2 2022, an estimated $1K.
- Integrity Capital Management (HK) first reported a position in Class Acceleration Corp. Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 in Q4 2021 and held it in 2 quarters.
- Integrity Capital Management (HK)'s Class Acceleration Corp. Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 position peaked at $26K in Q4 2021.
- 44 funds tracked by Wall St. Rank held Class Acceleration Corp. Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 as of Q2 2022.
Based on Integrity Capital Management (HK)'s 13F filing for Q2 2022.